R. Bahleda

发表

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience

O. Mir, J. Soria, E. Lanoy, 2016, International journal of cancer.

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy.

N. Magné, J. Pignon, A. Italiano, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

F. Meric-Bernstam, B. Tran, H. Arkenau, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors

F. Meric-Bernstam, B. Tran, H. Arkenau, 2020 .

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

M. Zucchetti, F. André, J. Tabernero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.

D. Planchard, G. Le Teuff, J. Soria, 2014, Lung cancer.

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

H. Kantarjian, J. Soria, J. Cortes, 2015, Leukemia research.

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Y. Drew, R. Plummer, J. Soria, 2013, Investigational New Drugs.

Pemetrexed-induced pneumonitis: a case report.

J. Soria, Y. Loriot, M. Wislez, 2009, Clinical lung cancer.

Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer

F. André, J. Tabernero, J. Soria, 2012 .

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

T. Baère, V. Lazar, J. Soria, 2013, Investigational New Drugs.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

T. de Baère, V. Lazar, J. Soria, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

M. Hidalgo, T. Nayak, K. Stubenrauch, 2017, Clinical Cancer Research.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

J. Blay, A. Tolcher, P. LoRusso, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab-induced laryngeal necrosis.

J. Soria, J. Bosq, D. Hartl, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.

P. LoRusso, J. Soria, H. Burris, 2015, The oncologist.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

J. Pignon, J. Soria, B. Besse, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.

A. Cesne, O. Mir, J. Adam, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials

D. Planchard, J. Soria, C. Bourgier, 2013, Oncology Research and Treatment.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial

L. Molinero, F. Kabbinavar, I. Braña, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.

J. Soria, B. Escudier, H. Izzedine, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor inhibitor (FGFRi), in patients with cholangiocarcinoma and FGFR pathway alterations previously treated with chemotherapy and other FGFRi's.

F. Meric-Bernstam, A. Zhu, B. Tran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer

M. Gizzi, Y. Loriot, R. Bahleda, 2019, Bladder Cancer.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma

Z. Wainberg, B. Ma, Y. Cheng, 2021, Annals of Oncology.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

R. Plummer, M. Ranson, J. Soria, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients

L. Zitvogel, A. Eggermont, N. Chaput, 2013, Oncoimmunology.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

Pazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysis.

J. Soria, D. Pérol, A. Hollebecque, 2013 .

970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

D. Cupissol, A. Marabelle, J. Fayette, 2020, Annals of Oncology.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

J. Pignon, J. Soria, B. Besse, 2015 .

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors

J. Soria, A. Awada, S. Aspeslagh, 2016, Anti-cancer drugs.

Identification of new prognostic factors in phase I patients treated by immunotherapy

J. Soria, J. Armand, V. Ribrag, 2016 .

Tumour growth rates and RECIST criteria in early drug development.

F. Bidault, J. Soria, S. Koscielny, 2011, European Journal of Cancer.

51P Pooled analysis safety profile of futibatinib in patients with advanced solid tumors, including intrahepatic cholangiocarcinoma (iCCA)

F. Meric-Bernstam, J. Furuse, J. Bridgewater, 2021, Annals of Oncology.

Profile and outcome of cancer patients enrolled in contemporary phase I trials.

Y. Loriot, V. Ribrag, S. Ammari, 2023, European Journal of Cancer.

Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours

J. Soria, H. Staines, A. Hollebecque, 2012 .

Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy - brachytherapy association.

C. Haie-meder, Cyrus Chargari, O. Mir, 2022, Oral oncology.

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

M. Hidalgo, T. Nayak, J. Albanell, 2014 .

Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013)

Y. Drew, R. Plummer, J. Soria, 2013 .

Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors".

M. Zucchetti, F. André, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer

N. Hanna, R. Herbst, F. Shepherd, 2008 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

J. Soria, J. Armand, C. Robert, 2016, European journal of cancer.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

J. Soria, C. Caramella, B. Besse, 2015, Lung cancer.

Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

B. Adamo, F. Debraud, F. Dubois, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A. Tolcher, J. Soria, V. Diéras, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors.

G. Shapiro, A. Berkenblit, J. Soria, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1044OLong-Term Safety and Clinical Outcomes of Atezolizumab in Head and Neck Cancer: Phase Ia Trial Results

F. Hodi, L. Molinero, I. Braña, 2017 .